Nimotop S (Nimodipine)

Nimodipine, the active ingredient in Nimotop S, is a calcium channel blocker presented as an oral formulation for oral use. It is used to prevent cerebral vasospasm following subarachnoid hemorrhage in patients who have experienced this type of bleed.

GNH USA supplies Nimotop S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine is indicated for conditions involving cerebral vasospasm and related vascular complications.

- Subarachnoid hemorrhage: prevents delayed cerebral ischemia by reducing vasospasm. - Aneurysmal SAH: improves neurological outcome through sustained cerebral vessel dilation. - Neurosurgical patients at risk of vasospasm: lowers incidence of post‑operative vessel narrowing.

Nimodipine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of skin. - Dizziness or light‑headedness. - Nausea or gastrointestinal discomfort. - Hypotension: mild blood pressure reduction. - Peripheral edema: swelling of lower limbs.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: abnormally slow heart rate. - Allergic reaction: rash, itching, or swelling. - Liver enzyme elevation: signs of hepatic stress. - Cardiac arrhythmia: irregular heart rhythm. - Neutropenia: reduced white blood cell count.

Before prescribing Nimodipine, clinicians should consider several safety aspects.

- Blood pressure monitoring: check for hypotension during therapy. - Hepatic impairment: use with caution in severe liver disease. - Cardiac conduction disorders: avoid in patients with advanced heart block. - Pregnancy and lactation: assess risk‑benefit as safety data are limited. - Concomitant vasodilators: monitor for additive blood pressure effects. - Store below 25°C: keep in the original pack, protect from moisture.

Nimodipine can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma levels. - Nitrates (e.g., nitroglycerin): additive hypotensive effect. - Other calcium‑channel blockers (e.g., verapamil): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce drug exposure. - Antihypertensive agents (e.g., ACE inhibitors, beta‑blockers): may enhance blood pressure lowering. - Diuretics: potential electrolyte disturbances. - Anticholinergic drugs: may increase dizziness. - NSAIDs: possible reduction in antihypertensive effect.